Trial tech firm Thread has acquired inVibe to add “voice research technology” to its decentralized offering to drug study sponsors and CROs.
The deal – financial terms of which were not disclosed – is based on inVibe’s voice research technology and consulting services.
InVibe also provides recruitment services designed to enable health care stakeholders to participate in quantitative and qualitative research with “minimal friction,” according to the firm.
Buying inVibe will differentiate his firm from the competition says Thread CEO John Reites.
“inVibe adds capabilities to the thread platform that allow us to integrate the power of voice into clinical research. This will help us as we seek to create the best possible trial experiences for participants and all other study stakeholders.
“The ability to analyze and integrate data from listening technology is currently missing from other top players in the industry. We are moving the needle when it comes to delivering adaptive, patient-centered research experiences.”
This was echoed by inVibe CEO, Fabio Gratton, who said, "Joining Thread will expedite the delivery of primary research with direct participant listening research via automated survey and voice data capture, and will alter the outcomes of new drugs in the marketplace."
The inVibe acquisition comes just months after Thread bought clinical trial consultancy group Modus Outcomes. Both deals were designed to expand Thread’s decentralized research business.
The firm has been building its decentralized trials business in the past few years, notably it September last year when it launched “Thread Adopt,” which is a consulting service to help sponsors determine if their planned trials could be run remotely.
At the time Thread told us that its approach differs from competitors because it looks at studies at the enterprise-level scale, providing the adoption and change management-focused templates, tools and thinking required for decentralized studies.
Image: Stock Photo Secrets